Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. ImprimisRx CA, Inc., dba ImprimisRx
WARNING LETTER
•ImprimisRx CA, Inc., dba ImprimisRx•March 31, 2017

ImprimisRx CA, Inc., dba ImprimisRx – FDA Warning Letter, Mar 31, 2017

Record Details

On March 26, 2019, the FDA issued a Warning Letter to ImprimisRx CA, Inc., dba ImprimisRx, following a March 27-31, 2017, inspection. The inspection was prompted by a MedWatch report of a patient's death after receiving IV curcumin compounded by ImprimisRx.

The FDA found that ImprimisRx's compounded drug products failed to meet Section 503A of the FDCA conditions for exemption from CGMP, adequate directions for use, and FDA approval. Specifically, the firm compounded drugs using GHRP-2, GHRP-6, green tea extract, and artesunate, which are not eligible for 503A exemptions.

Violations included adulterated drug products due to insanitary conditions (e.g., visible stains on ISO-5 hood HEPA filters, inadequate protection studies), sub-potency (curcumin concentrations significantly lower than labeled), and contamination with Diethylene Glycol (DEG) from ungraded PEG 40 castor oil. The firm also failed to establish adequate environmental monitoring, equipment maintenance, and aseptic processing procedures, leading to CGMP violations (21 CFR 211.42(c)(10)(iv), 211.42(c)(10)(vi), 211.113(b)).

Furthermore, the ineligible drug products were un

Company
ImprimisRx CA, Inc., dba ImprimisRx
Inspection date
March 31, 2017
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations IV
People
  • Jessica Mu (Ms.)
  • Steven E. Porter (Program Division Director)
View Company Profile

ID · 7493c3fa-c636-4f9e-88cb-c56719d06e12

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 351(a)(2)(B)21 U.S.C. 353a21 U.S.C. 352(f)(1)21.U.S.C. 355(a)21 U.S.C. 351(a)(2)(A)21 U.S.C. 351(c)21 U.S.C. 351(d)21 U.S.C. 331(d)21 U.S.C. 321(p)

Full citation text and observation details available on the Dashboard.

Other documents for ImprimisRx CA, Inc., dba ImprimisRx
  • 483 - 2017-03-31March 31, 2017
  • 483 - 2016-03-14March 14, 2016
  • 483 - 2014-07-02July 2, 2014
  • STATE_REFERRAL_LETTER - 2014-06-23June 23, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore ImprimisRx CA, Inc., dba ImprimisRx
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.